This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of September 2016. Because of its value to the laboratory community, it is being retained in CLSI’s library.

H30-A2

Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition

This document provides guidance on performing the fibrinogen assay in the clinical laboratory. Topics addressed include reporting of results and \textit{in vivo} and \textit{in vitro} conditions that may alter results.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeals Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org
Abstract

Clinical and Laboratory Standards Institute document H30-A2—Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition—is a performance guideline for laboratory and/or clinical healthcare professionals responsible for the routine performance of fibrinogen assays. This guideline describes a technique, based on the method described by Clauss,1 that is practical, precise, and widely used in the clinical laboratory. Preanalytical and analytical factors and conditions that may alter results are discussed.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Contents

Abstract .................................................................................................................................................... i
Committee Membership ........................................................................................................................ iii
Active Membership ......................................................................................................................................... v
Foreword ............................................................................................................................................. xiii

1 Introduction ................................................................................................................................ 1
2 Scope .......................................................................................................................................... 1
3 Standard Precautions .................................................................................................................. 1
4 Definitions ..................................................................................................................................... 1
5 Principle ..................................................................................................................................... 2
6 Equipment .................................................................................................................................. 2
   6.1 Containers ..................................................................................................................... 2
   6.2 Delivery Systems .......................................................................................................... 2
   6.3 Heating Block ............................................................................................................... 2
7 Specimen Handling ...................................................................................................................... 3
   7.1 Patient Information ....................................................................................................... 3
   7.2 Specimen Collection, Transportation, Processing, and Storage ................................... 3
   7.3 Post-test Specimen Management .................................................................................. 3
8 Reagents ..................................................................................................................................... 3
   8.1 Commercial Reagents ................................................................................................... 3
   8.2 Non-Commercial Reagents ........................................................................................... 3
9 Reference Curve................................................................................................................................. 4
10 Procedure ................................................................................................................................... 6
11 Test Result Management ............................................................................................................ 6
12 Considerations in Performing the Fibrinogen Assay ................................................................. 7
   12.1 Manufacturers’ Instructions .......................................................................................... 7
   12.2 Water ............................................................................................................................. 7
   12.3 Cleaning ........................................................................................................................ 7
   12.4 Temperature .................................................................................................................. 7
   12.5 End Point Determination ............................................................................................. 7
   12.6 Quality Control ............................................................................................................. 7
   12.7 Reference Interval ......................................................................................................... 7
13 Sources of Preanalytical Error ...................................................................................................... 8
   13.1 Inappropriate Specimen Collection ................................................................................ 8
14 Sources of Analytical Error ........................................................................................................ 8
Contents (Continued)

14.1 Inappropriate Thrombin Preparation ................................................................. 8
14.2 Incorrect Conditions ......................................................................................... 8
14.3 Paraproteins ...................................................................................................... 8
14.4 Bovine Thrombin Antibodies ........................................................................... 9
14.5 Fibrin/Fibrinogen Degradation Products (FDP) ............................................... 9
14.6 Heparin ............................................................................................................ 9
14.7 Dysfibrinogenemia ........................................................................................... 9

References .................................................................................................................. 10

Summary of Comments and Subcommittee Responses .............................................. 11

Summary of Delegate Comments and Subcommittee Responses ......................... 12

Related NCCLS Publications ..................................................................................... 15
Foreword

One of the major physiological roles of the coagulation system is to stop the loss of blood by generating a fibrin meshwork at the site of trauma or injury by converting the plasma glycoprotein fibrinogen to the fibrin polymer mesh. Numerous pathological conditions can induce decreased levels of fibrinogen rendering the coagulation system unable to generate sufficient fibrin to halt the blood loss. Increased levels of fibrinogen have been associated with cardiovascular disease and thrombosis. Decreased or increased levels of fibrinogen are clinically relevant and must be accurately determined. Laboratories should establish a normal reference interval for fibrinogen measurements. Generally, the normal reference interval is 150 to 350 mg/dL (1.5 to 3.5 g/L).

Fibrinogen, a β-globulin, is deficient in congenital afibrinogenemia and hypofibrinogenemia; in some cases of dysfibrinogenemia; and in a variety of acquired states, such as disseminated intravascular coagulation, systemic hyperfibrinolysis, severe hepatic dysfunction, and after treatment with L-asparaginase or sodium valproate. Spontaneous bleeding is usually not seen in patients with selected hypofibrinogenemia, i.e., fibrinogen levels of 50 to 100 mg/dL (0.5 to 1.0 g/L); however with certain types of hemostatic stress (surgery, trauma) bleeding may occur at levels up to 100 mg/dL (1.0g/L).

Fibrinogen is an acute phase reactant (i.e., a variety of physiologic stimuli or stresses such as pregnancy, inflammatory states, or estrogen use cause elevation of the plasma fibrinogen). Sustained progressive increases in fibrinogen within the upper 50th percentile of the normal reference interval or persistently elevated fibrinogen levels have increased risk of arterial and venous thrombosis (a prethrombotic state or a hypercoagulable state). Elevated fibrinogen levels have been implicated as a possible risk factor for the development of arterial and venous thrombotic complications. Consequently, fibrinogen levels may be more widely used in the future for the assessment of the risk of developing thrombotic complications.

A number of assays of plasma fibrinogen have been described which are based on measurements of total clottable fibrinogen by protein assay,7,8 changes in turbidity or light scattering,9 salt precipitation,10 and fibrinogen antigen by various immunologic methods.2,11 This document also describes a specific technique for the determination of fibrinogen concentration based on the Clauss thrombin clotting rate assay.1 This assay is practical, precise, and widely used in the clinical laboratory. This document is primarily directed toward laboratory and/or clinical personnel responsible for obtaining and processing blood specimens, performing the fibrinogen assay and quality control procedures, and reporting fibrinogen assay results. It is also intended as a guide for manufacturers of the reagents and instruments. Preanalytical and analytical factors and conditions that may alter results are discussed.

Other international standards procedures have been established for determination of fibrinogen in plasma. This guideline was separately from standards for fibrinogen determination prepared by the Deutches Institut für Normung (DIN).12,13 On comparison, the documents appear to be essentially the same. Some differences do occur based on available and standard reagents. Use of either should allow determination of fibrinogen concentration. NCCLS will work toward harmonization in the next revision of H30.

The Quality System Approach

NCCLS subscribes to a quality system approach in the development of standards and guidelines, which facilitates project management; aids in defining document structure; and provides a process to identify needed documents through a gap analysis. The approach is based on the model presented in the most current edition of NCCLS document GP26—A Quality System Model for Health Care.
Foreword (Continued)

The quality system approach applies a core set of “quality system essentials,” basic to any organizational process, to all operations in the healthcare service’s path of workflow. The quality system essentials are: organization; personnel; equipment; purchasing and inventory; process control; documents and records; occurrence management; internal assessment; process improvement; service and satisfaction; facilities and safety; and information management. The path of workflow for the clinical laboratory consists of three process areas: preanalytical; analytical; postanalytical.

NCCLS document H30-A2—Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition describes the preanalytical and analytical aspects of the path of workflow for the clinical laboratory by specifically providing guidance on the collection, transportation, handling, and storage of the specimen or sample and on performing fibrinogen assays in the laboratory.

Key Words

Afibrinogenemia, Clauss method, disseminated intravascular coagulation (DIC), dysfibrinogenemia, fibrin, fibrinogen, hypofibrinogenemia
1 Introduction

This document specifies a technique to assay fibrinogen in plasma, based on the method of Clauss.¹

2 Scope

H30-A2 contains guidelines for the collection, transportation, handling, and storage of blood specimens or plasma samples and general guidelines for performing the fibrinogen assay by the Clauss method.¹ It is primarily directed toward laboratory and/or clinical personnel responsible for obtaining and processing blood specimens, performing the fibrinogen assay and quality control procedures, and reporting fibrinogen assay results. It is also intended as a guide for manufacturers of the reagents and instruments. The guideline does not cover prothrombin-time (PT)-derived fibrinogen determination which can be performed using various automated coagulation instruments.¹⁴

3 Standard Precautions

Because it is often impossible to know what might be infectious, all human blood specimens are to be treated as infectious and handled according to “standard precautions.” Standard precautions are new guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of any pathogen and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-borne pathogens. Standard precaution and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (Guideline for Isolation Precautions in Hospitals. Infection Control and Hospital Epidemiology. CDC. 1996;Vol 17;1:53-80.). [MMWR 1987;36(suppl 2S):2S-18S] and (MMWR 1988;37:377-382, 387-388). For specific precautions for preventing the laboratory transmission of blood-borne infection from laboratory instruments and materials; and recommendations for the management of blood-borne exposure, refer to NCCLS document M29—Protection of Laboratory Workers from Instrument Biohazards and Infectious Disease Transmitted by Blood, Body Fluids, and Tissue.

4 Definitions*¹

Control (plasma), n - A batch of citrated plasma used to monitor the stability of the laboratory test system, which includes reagents, instruments, reconstituting and diluting fluids, and pipettes; NOTES: a) “Normal control plasma” gives test results within the range of the reference interval; b) “Abnormal control plasmas” for factor assays should contain factor concentrations below the reference interval values due to abnormally low factor concentrations; c) If factors are clinically elevated, the “abnormal control plasma” should contain factor concentrations above the reference interval; d) Normal and abnormal control plasmas may be prepared in the laboratory or obtained commercially.

Reference curve, n - A line, typically a straight line, that defines the quantitative relationship between an independent variable and a dependent variable; NOTE: From this line the observed output of an analytic procedure (e.g., APTT test) can be converted to the units of measurement of the analyte of interest (e.g., coagulation factor activity).

*¹ Some of these definitions are found in NCCLS document NRSCL8—Terminology and Definitions for Use in NCCLS Documents. For complete definitions and detailed source information, please refer to the most current edition of that document.

©Clinical and Laboratory Standards Institute. All rights reserved.
Related NCCLS Publications*

**C3-A3** Preparation and Testing of Reagent Water in the Clinical Laboratory; Approved Guideline—Third Edition (1997). This document provides guidelines on water purified for clinical laboratory use; methods for monitoring water quality and testing for specific contaminants; and water system design considerations.

**C28-A2** How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline—Second Edition (2000). This document contains guidelines for determining reference values and reference intervals for quantitative clinical laboratory tests.


**H3-A4** Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard—Fourth Edition (1998). This document provides procedures for the collection of diagnostic specimens by venipuncture, including line draws, blood culture collection, and venipuncture in children. It also includes recommendations on order of draw.

**H21-A3** Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline—Third Edition (1998). This guideline contains procedures for collecting, transporting, and storing blood, processing blood specimens, storing plasma for coagulation testing, and provides general recommendations for performing the tests.

**H47-A** One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline (1996). This document provides guidelines for performing the PT and APTT tests in the clinical laboratory, for reporting results, and for identifying sources of error.

**H48-A** Determination of Factor Coagulant Activities; Approved Guideline (1997). A consolidation of Factor VIII and Factor IX assays guidelines, this document addresses the performance, quality control, and reporting of assays for coagulation factor activity based upon conventional APTT and PT coagulation tests.

**M29-A** Protection of Laboratory Workers from Instrument Biohazards and Infectious Disease Transmitted by Blood, Body Fluids, and Tissue; Approved Guideline (1997). This document offers guidance on the risk of transmission of hepatitis viruses and human immunodeficiency viruses in the laboratory; gives specific precautions for preventing transmission of blood-borne infection from laboratory instruments and materials; and recommendations for the management of blood-borne exposure.

* Proposed- and tentative-level documents are being advanced through the NCCLS consensus process; therefore, readers should refer to the most recent editions.

© Clinical and Laboratory Standards Institute. All rights reserved.
Related NCCLS Publications (Continued)

NRSCN8-A Terminology and Definitions For Use in NCCLS Documents; Approved Standard (1998). This document provides standard definitions for use in NCCLS standards and guidelines, and for submitting candidate reference methods and materials to the National Reference System for the Clinical Laboratory (NRSCN).
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI’s efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at clsi.org/eCLIPSE.

For more information, visit www.clsi.org today.